Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab in children and adolescents with hypereosinophilic syndrome
NL-OMON51313Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mepolizumab in hypereosinophilic syndrome (HES), sponsored by GSK. Primary endpoint: Frequency of HES flares over the 52-week study treatment period. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
mepolizumab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on NL-OMON51313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51313.